PremiumThe FlyBausch Health price target lowered to $8 from $9 at Raymond James Bausch Health price target lowered to $8 from $9 at Raymond James Bausch Health Companies: Hold Rating Amid Lowered Earnings and Profitability Concerns PremiumThe FlyBausch Health options imply 9.1% move in share price post-earnings Bausch Health announces Health Canada clearance of Solta’s Thermage FLX system Bausch Health Companies (BHC) Q1 Earnings Cheat Sheet PremiumCompany AnnouncementsU.S. District Court Rules in Favor of Bausch Health and FDA in XIFAXAN Case Bausch says court grants summary judgment in favor of FDA, Salix, and Teva Bausch Health Adopts Shareholder Rights Plan to Ensure Fair Treatment 
